Product Description:

• 
  

  The fixed-dose combination of ledipasvir-sofosbuvir and provides an effective and well-tolerated one-pill once-a-day option for treatment of genotypes 1, 4, 5, and 6 chronic hepatitis C (HCV) infection.

  
  


• 
  

  This direct-acting antiviral regimen was the first FDA-approved interferon- and ribavirin-free regimen to treat hepatitis C.

  
  


• 
  

  Ledipasvir-sofosbuvir can be used without ribavirin in most patients with genotype 1A, except those who are cirrhotic and treatment-experienced.

  
  


• 
  

  In addition, persons with HCV genotype 1 may be eligible for an 8-week duration if they are treatment-naïve, without cirrhosis, and have a pretreatment HCV RNA level less than 6 million. Similar to sofosbuvir-velpatasvir, the other NS5B-NS5A inhibitor combination, ledipasvir-sofosbuvir is safe and effective for the treatment of HCV in persons with decompensated cirrhosis.

  
  

How to use:

• 
  

  Ledipasvir-sofosbuvir (90 mg/400 mg) is a fixed-dose combination tablet.

  
  


• 
  

  The recommended dosage is one tablet once daily, with or without food.

  
  

Caution & Warnings:

• 
  

  Risk of HBV reactivation in patients coinfected with HCV and HBV.

  
  

Side Effects:

• Fatigue and headache.

Ingredients:

• Ledipasvir, sofosbuvir 90mg/400mg.